What is the 13F Pro Quality Score for ALLO?

13F Pro ranks Allogene Therapeutics, Inc. (ALLO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ALLO's current score at https://13fpro.ai/company/ALLO (free sign-up required for the full ranking).

Which hedge funds own the most ALLO stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ALLO include BlackRock,, PFIZER, Frazier Life Sciences Management, L.P.. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/ALLO as soon as new 13F filings post.

Where does 13F Pro source ALLO data?

All Allogene Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Allogene Therapeutics, Inc. files with the SEC under CIK 1737287. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ALLO in?

Allogene Therapeutics, Inc. (ALLO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ALLO research updated on 13F Pro?

ALLO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Allogene Therapeutics, Inc.(ALLO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1737287 ALLO stock profile & AI dashboard →

13F Pro Quality Score

33.9/100

Rank #2,371 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

99.3/100

Profitability

1.5/100

Balance Sheet

7.1/100

Earnings Quality

30.6/100

Free Cash Flow

1.5/100

Institutional Flow

95.0/100

Revenue Scale

1.7/100

Dilution Risk

0.6/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ALLO Scores 34/100

exact factor attribution · 2026-09-11

ALLO's composite is driven by revenue growth and earnings growth, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.9 pts

99th pct

Earnings growth

+2.3 pts

95th pct

Institutional flow

+2.3 pts

95th pct

Earnings quality

-1.9 pts

31th pct

Shareholder dilution

-2.5 pts

1th pct

Capital efficiency

-4.3 pts

7th pct

Scale

-7.2 pts

2th pct

Profitability

-7.3 pts

2th pct

Free cash flow

-7.3 pts

2th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ALLO Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Allogene Therapeutics, Inc. (ALLO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ALLO at 33.9/100 on a 32-signal composite quality model, placing it at rank #2,371 of 2,962 stocks — the bottom half of the AI-ranked universe. ALLO scores in the top quartile across revenue growth (99.3), institutional flow (95.0). Areas of concern include profitability (1.5) and free cash flow (1.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Allogene Therapeutics, Inc. reports quarterly revenue of $4.6M, net income of $-42.7M, free cash flow of $-32.1M. Top institutional holders of ALLO by reported 13-F value include BlackRock, PFIZER, Frazier Life Sciences Management, L.P., based on the most recent SEC filings. ALLO trades on the Nasdaq exchange and files with the SEC under CIK 1737287. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALLO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Allogene Therapeutics, Inc. directly from SEC EDGAR. Allogene Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 3 and 34 since 2024, currently 33.9 — an improving long-term trajectory across 25 quarterly and live scoring snapshots.

Revenue

Q2 2026

$4.6M

Net Income

Q2 2026

$-42.7M

Free Cash Flow

Q2 2026

$-32.1M

ROIC

Q2 2026

-43.0%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-100.0% YoY

$0.00FY 2025

FY22 $156.0KFY23 $95.0KFY24 $22.0KFY25 $0.00

Net Income

+25.9% YoY

$-190.9MFY 2025

FY22 $-1.24BFY23 $-1.56BFY24 $-257.6MFY25 $-190.9M

Operating Income

+23.4% YoY

$-209.3MFY 2025

FY22 $-335.5MFY23 $-327.7MFY24 $-273.2MFY25 $-209.3M

EPS (Diluted)

+34.1% YoY

$-0.87FY 2025

FY22 $-2.38FY23 $-2.09FY24 $-1.32FY25 $-0.87

Total Assets

-24.2% YoY

$415.9MFY 2025

FY22 $821.6MFY23 $642.8MFY24 $548.7MFY25 $415.9M

Op. Cash Flow

+25.5% YoY

$-149.2MFY 2025

FY22 $-220.5MFY23 $-237.7MFY24 $-200.3MFY25 $-149.2M

Free Cash Flow

+25.6% YoY

$-149.6MFY 2025

FY22 $-225.7MFY23 $-239.2MFY24 $-201.0MFY25 $-149.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$0.00 -100.0%	$22.0K -76.8%	$95.0K -39.1%	$156.0K -99.9%	$114.1M	$0.00
Net Income	$-190.9M +25.9%	$-257.6M +83.5%	$-1.56B -26.5%	$-1.24B -36.7%	$-903.3M -39.8%	$-646.3M
Operating Income	$-209.3M +23.4%	$-273.2M +16.6%	$-327.7M +2.3%	$-335.5M -86.2%	$-180.2M +30.2%	$-258.2M
EPS (Diluted)	$-0.87 +34.1%	$-1.32 +36.8%	$-2.09 +12.2%	$-2.38 -77.6%	$-1.34 +49.0%	$-2.63
Total Assets	$415.9M -24.2%	$548.7M -14.6%	$642.8M -21.8%	$821.6M -21.8%	$1.05B -14.4%	$1.23B
Operating Cash Flow	$-149.2M +25.5%	$-200.3M +15.7%	$-237.7M -7.8%	$-220.5M -19.3%	$-184.8M -60.6%	$-115.1M
Free Cash Flow	$-149.6M +25.6%	$-201.0M +16.0%	$-239.2M -6.0%	$-225.7M -9.4%	$-206.3M -13.9%	$-181.1M

Get alerted when ALLO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Allogene Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ALLO

BlackRock, Inc.
$62.7M30,146,963 sh
PFIZER INC
$46.9M22,032,040 sh
Frazier Life Sciences Management, L.P.
$46.7M22,446,668 sh
STATE STREET CORP
$39.6M19,025,826 sh
TPG GP A, LLC
$38.9M18,716,306 sh
Sio Capital Management, LLC
$27.7M13,323,431 sh
PRIMECAP MANAGEMENT CO/CA/
$27.3M13,123,440 sh
VANGUARD CAPITAL MANAGEMENT LLC
$25.3M12,166,636 sh
FMR LLC
$25.0M12,009,043 sh
CITADEL ADVISORS LLC
$21.0M10,087,770 sh

Fund	Value	Shares
BlackRock, Inc.	$62.7M	30,146,963
PFIZER INC	$46.9M	22,032,040
Frazier Life Sciences Management, L.P.	$46.7M	22,446,668
STATE STREET CORP	$39.6M	19,025,826
TPG GP A, LLC	$38.9M	18,716,306
Sio Capital Management, LLC	$27.7M	13,323,431
PRIMECAP MANAGEMENT CO/CA/	$27.3M	13,123,440
VANGUARD CAPITAL MANAGEMENT LLC	$25.3M	12,166,636
FMR LLC	$25.0M	12,009,043
CITADEL ADVISORS LLC	$21.0M	10,087,770

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ALLO on your watchlist

Track score changes the day Allogene Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ALLO a good stock to buy?

13F Pro's AI-powered analysis of Allogene Therapeutics, Inc. (ALLO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ALLO are available on the ALLO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ALLO is classified as a small company.

Which hedge funds own ALLO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ALLO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Allogene Therapeutics, Inc.'s investment landscape.